Status:
RECRUITING
ACT Lung Health Intervention: Phase Two
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
National Cancer Institute (NCI)
University of Massachusetts, Boston
Conditions:
Smoking Cessation
Smoking Behaviors
Eligibility:
All Genders
50-80 years
Phase:
NA
Brief Summary
This study aims to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.
Detailed Description
This two-arm stratified randomized clinical trial is to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at h...
Eligibility Criteria
Inclusion
- Self-identify as either Chinese or Korean
- Speak either Korean, Mandarin, or English
- Eligible for LDCT screening (50-80 years of age and 20- pack-year smoking history)
- Currently smoking (i.e., having smoked within the prior 30 days),
- Currently have active health insurance coverage and a primary healthcare provider and
- Have access to a video-call device with internet or wireless connection.
- Eastern Cooperative Oncology Group functional status \<2
- Live in the United States for the next 12 months
Exclusion
- Had LDCT screening done within the last 2 years.
- Hospitalization due to a serious mental illness (e.g., psychotic disorders) during the prior 6 months.
- Previous history of lung cancer.
- We will not include any of the following special populations:
- Adults unable to consent.
- Adults younger than 50 or older than 80 years
- Individuals who are not yet adults (infants, children, teenagers)
- Pregnant women
- Prisoners
Key Trial Info
Start Date :
November 4 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT06945120
Start Date
November 4 2025
End Date
December 31 2026
Last Update
November 13 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115